John A Orwin's Net Worth

$16.3 Million

Estimate Recalculated Apr 25, 2026 02:11PM EST

Who is John A Orwin

John A Orwin has an estimated net worth of $16.3 Million. This is based on reported shares across multiple companies, which include SEATTLE GENETICS INC /WA, Relypsa Inc, NeurogesX Inc, CARGO Therapeutics, Inc., Travere Therapeutics, Inc., Atreca, Inc., AFFYMAX INC, ARRAY BIOPHARMA INC, and ANAPTYSBIO, INC.

SEC CIK

John A Orwin's CIK is 0001477384

Past Insider Trading and Trends

2012 was John A Orwin's most active year for acquiring shares with 16 total transactions. John A Orwin's most active month to acquire stocks was the month of April. 2012 was John A Orwin's most active year for disposing of shares, totalling 23 transactions. John A Orwin's most active month to dispose stocks was the month of November. 2014 saw John A Orwin paying a total of $537,125.00 for 157,000 shares, this is the most they've acquired in one year. In 2023 John A Orwin cashed out on 120,885 shares for a total of $6,650,284.44, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Seagen Inc.

Investor
Updated Dec 15, 2023
Dec 14
31.05KMay 31
32.68KMay 13
30.96KMay 14
29.27KMay 15
31.80KMay 20
31.06KMay 18
27.36KMay 19
23.66KMay 20
Feb 12
17.96KMay 15
Jan 10
Showing 13 results

Relypsa Inc

President & CEO
Updated Sep 02, 2016
Sep 01
Aug 15
Jun 03
ScheduledDec 07
ScheduledDec 02 - Dec 04
59.38KNov 06
ScheduledAug 17
152.50KAug 10
ScheduledJul 30 - Jul 31
ScheduledMay 29 - Jun 01
129.50KAug 14
Nov 20
Showing 13 results

NeurogesX Inc

Investor
Updated Jun 11, 2012
10.00KJun 07
50.00KFeb 07
10.00KJun 02
10.00KJun 02
20.00KNov 19
Showing 6 results

CARGO Therapeutics, Inc.

Investor
Updated Jun 06, 2024
23.74KJun 04
25.00KNov 09
Showing 3 results

Travere Therapeutics, Inc.

Investor
Updated May 10, 2024
48.38KMay 08
35.88KMay 17
26.88KMay 11
23.88KMay 14
20.88KMay 15
16.88KMay 08
16.88KMay 09
21.88KMar 23
Showing 9 results

Atreca, Inc.

PRESIDENT & CEO
Updated Apr 17, 2024
Apr 11
Sep 01
535.49KFeb 09
Sep 02
708.75KJun 13
381.40KDec 23
121.40KSep 09
260.00KJan 27
Mar 17
241.00KFeb 26
Showing 11 results

AFFYMAX INC

CEO
Updated Jun 28, 2013
ScheduledJun 27 - Jun 28
ScheduledFeb 01
236.00KJan 30
ScheduledDec 03
ScheduledOct 05
ScheduledOct 01
ScheduledSep 13
ScheduledAug 20
ScheduledAug 01
ScheduledJul 13
ScheduledApr 27
ScheduledApr 03
ScheduledMar 27
ScheduledFeb 02
313.00KJan 31
ScheduledAug 18
460.00KFeb 01
140.00KSep 22
220.00KApr 12
Showing 20 results

ARRAY BIOPHARMA INC

Investor
Updated Jul 30, 2019
Jul 30
40.00KOct 25 - Oct 26
Oct 26 - Oct 27
Oct 27 - Oct 29
30.00KOct 29
25.00KOct 30
25.00KOct 23
Showing 8 results

ANAPTYSBIO, INC

Investor
Updated Sep 17, 2024
5.94KSep 15
2.04KJun 15
22.54KJan 03
19.85KSep 15
Showing 5 results